Selected ongoing or recently completed trials for untreated older patients with acute myeloid leukemia (AML).
| Group . | Age . | Trial . |
|---|---|---|
| CALGB | >60 | Randomized Phase III Trial Comparing Daunorubicin/Ara-C With or Without Oblimersen (bcl-2 antisense) |
| ECOG | >60 | Randomized Phase III Trial Comparing Daunorubicin/Ara-C with or Without L4335979 (MDR Modulator, Zosuquidar) |
| SWOG | >55 | Randomized Phase III Trial Comparing Continuous Infusion Daunorubicin/Ara-C With or Without Cyclosporine A (MDR Modulator) Followed by Assignment to Reduced Intensity Allogeneic HSCT (if HLA-matched Donor) |
| EORTC | >60 | Randomized Phase III Trial Comparing Idarubicin/Ara-C With or Without Gemtuzumab Ozogomycin (conjugated anti-CD33 with Calicheamycin) |
| HOVON | >60 | Randomized Trial comparing Different Doses of Daunorubicin/Ara-C Induction and Consolidation Followed by Gemtuzumab Ozogomycin Maintenance versus Observation |
| MRC | >60 | Comparison of Intensive Chemo (Daunorubicin/Ara-C at various doses) versus Non-Intensive Chemo (Hydroxyurea/low dose Cytarabine ± ATRA) |
| US Intergroup | >60 | Phase II Study comparing two different schedules and doses of the farnesyl transferase inhibitor, R115777 (Tipifarnib, Zarnestra) |
| Group . | Age . | Trial . |
|---|---|---|
| CALGB | >60 | Randomized Phase III Trial Comparing Daunorubicin/Ara-C With or Without Oblimersen (bcl-2 antisense) |
| ECOG | >60 | Randomized Phase III Trial Comparing Daunorubicin/Ara-C with or Without L4335979 (MDR Modulator, Zosuquidar) |
| SWOG | >55 | Randomized Phase III Trial Comparing Continuous Infusion Daunorubicin/Ara-C With or Without Cyclosporine A (MDR Modulator) Followed by Assignment to Reduced Intensity Allogeneic HSCT (if HLA-matched Donor) |
| EORTC | >60 | Randomized Phase III Trial Comparing Idarubicin/Ara-C With or Without Gemtuzumab Ozogomycin (conjugated anti-CD33 with Calicheamycin) |
| HOVON | >60 | Randomized Trial comparing Different Doses of Daunorubicin/Ara-C Induction and Consolidation Followed by Gemtuzumab Ozogomycin Maintenance versus Observation |
| MRC | >60 | Comparison of Intensive Chemo (Daunorubicin/Ara-C at various doses) versus Non-Intensive Chemo (Hydroxyurea/low dose Cytarabine ± ATRA) |
| US Intergroup | >60 | Phase II Study comparing two different schedules and doses of the farnesyl transferase inhibitor, R115777 (Tipifarnib, Zarnestra) |